Hikma Pharmaceuticals has prepared a combined Prospectus that contains the formal notice of meeting for the general meeting, to be held on 19 February 2016, regarding the acquisition of Roxane Laboratories and Boehrniger Ingelheim Roxane from Boehringer.
Hikma Pharmaceuticals announced on 28 July 2015 that it had agreed terms to the acquisition.
Hikma revealed on Friday that the prospectus and circular which contains further details of the Acquisition has been published and will be posted to shareholders.
The Prospectus has been prepared by Hikma in relation to the admission to the premium listing segment of the Official List and to trading on the London Stock Exchange of 40,000,000 Consideration Shares of 10 pence each in Hikma and for the purposes of, among other things, seeking shareholder approval for the Acquisition.
The Consideration Shares will be issued and allotted to Boehringer Ingelheim on completion of the Acquisition.